tirzepatide and kidney disease landmark trial for masld Not currently a therapy. But this exploratory finding is worth watching closely. 🫘 #ObesityMedicine # Tirzepatide #Type2Diabetes #KidneyHealth #ChronicKidneyDisease #GLP1 #GIP #CardiometabolicHealth New Trial Studying Tirzepatide for

On the other hand, ActRII, a target addressing muscle loss during weight reduction, has made significant progress

Sometimes it is referred to as GLP-3 because it is a 3rd-generation triple agonist targeting 3 receptors, unlike Ozempic, which targets a single receptor

We start with the patient: weight history, prior attempts, family history, blood pressure, glucose, cholesterol, liver markers, sleep, medications, mental health, alcohol use, menopause or PMOS context when relevant, and what the patient is actually trying to accomplish

Within the TMD, we observed large structural shifts compared to the active peptide-bound structures, particularly in the extracellular halves of the TMD in the GLP-1RFab7F38 structure

Every dose is double what they intended